When Congress does something that people think was done right, like reauthorizing the Small Business Innovation Research program, we shouldn’t hesitate to say so.
I wrote about Congress reauthorizing the SBIR and Small Business Technology Transfer programs, which have been widely used by life sciences startups. In my article, I quoted Brian Wamhoff, co-founder and head of innovation for the Virginia-based biopharma HemoShear Therapeutics LLC, who said, “Thank you Congress for reauthorizing the SBIR and STTR programs.” Congress’s action “is huge for the biotech industry,” he said.
Congress acknowledged they were working to get it right this time because they didn’t do so well with it last time. The SBIR/STTR programs, which are funded from set asides from the R&D budgets of participating federal agencies, received 14 short-term extensions before Congress was able to pass the last reauthorization in 2012. The lawmakers were only able to get it through by making it part of the National Defense Authorization Act.
In 2016, Senate and House committee chairs acted to avoid this bottleneck and started the reauthorization process two years before the programs were due to expire in September 2017. They held hearings, ironed out differences, and on Dec. 23, 2016, President Obama signed the NDAA, which again included the reauthorization for the SBIR/STTR programs. They are now reauthorized through Sept. 30, 2022.
In contrast to five years ago, the new law was signed with little fanfare. Congress did its job ahead of schedule and without drama, which is probably why it didn’t receive much notice except for my Bloomberg BNA articles and a few more.
For the life sciences industry and for Congress, it was nice to end a year with a win.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)